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We investigated the diagnostic value and the relationship with clinicopathological features of total and free prostate-speciﬁc
antigen by measuring the concentrations of these markers in the sera of 75 women with colorectal carcinoma and in 30
healthy women. Measurements were performed by immunoradiometric assay which utilizes monoclonal and polyclonal anti-
prostate-speciﬁc antigen antibodies; the lowest detection level for both markers was 0.01 ng ml
71. Free prostate-speciﬁc
antigen levels were signiﬁcantly higher in women with colorectal carcinoma than healthy women (P=0.006). The percentage of
free prostate-speciﬁc antigen predominant (free prostate-speciﬁc antigen/total prostate-speciﬁc antigen 450%) subjects was
20% in colorectal carcinoma patients and 3.3% in healthy women (P=0.035). Cut-off values were 0.34 ng ml
71 for total
prostate-speciﬁc antigen and 0.01 ng ml
71 for free prostate-speciﬁc antigen. In women with colorectal carcinoma, total
prostate-speciﬁc antigen positivity was 20% and free prostate-speciﬁc antigen positivity was 34.6%. When compared to
negatives, total prostate-speciﬁc antigen positive patients had a lower percentage of well-differentiated (P=0.056) and early
stage (stages I and II) tumours (P=0.070). However, patients with predominant free prostate-speciﬁc antigen, had a higher
percentage of well-differentiated (P=0.014) and early stage tumours (P=0.090) than patients with predominant bound
prostate-speciﬁc antigen. In conclusion, although the sensitivity of free prostate-speciﬁc antigen predominancy is low (20%), in
distinguishing women with colorectal carcinoma than healthy women, its speciﬁcity is high (96.7%). Free prostate-speciﬁc
antigen predominancy tends to be present in less aggressive tumours. These ﬁndings may indicate clinical signiﬁcance of
preoperative measurement of serum total and free prostate-speciﬁc antigen in women with colorectal carcinoma.
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It has been shown by immunoﬂuorometric and immunohisto-
chemical assays that prostate-speciﬁc antigen (PSA) which is
widely utilized for the diagnosis and management of prostate
cancer, is not speciﬁc for the prostate gland itself but it also exists
in breast, ovarian, endometrial, kidney, adrenal and salivary gland
cancer tissues (Diamandis and Yu, 1997). Recently, molecular
forms of PSA (a1-antichymotripsin-bound PSA and free PSA) have
been investigated in the sera of women with benign and malignant
breast diseases and it has been reported that existence of free PSA
as the major molecular form may be of diagnostic importance in
female breast cancer (Borchert et al, 1997; Black et al, 2000).
The production of PSA in the prostate is up-regulated by andro-
gens, through the androgen receptor (Young et al, 1991; Henttu et
al, 1992; Luke and Coffey, 1994). The gene expression and protein
production of PSA in nonprostatic tissues are under the regulation
of steroid hormones via their receptors; androgens, glucocorticoids,
mineralocorticoids and progestins up-regulate the PSA production;
oestrogens down-regulate indirectly the PSA production induced
by androgens (Yu et al, 1994b; Zarghami et al, 1997). The existence
of androgen, progesterone and oestrogen receptors has been
demonstrated in colorectal cancer tissues (Meggouh et al, 1991;
Singh et al, 1993; Korenaga et al, 1997, 1998). The relation between
colorectal cancer and steroid hormone receptors may indicate the
existence of PSA in cancer tissues.
IthasbeenreportedthatPSAexpressionisnotfound(vanKrieken,
1993)orwheneverexisted,itisfoundintraceamounts(Levesqueetal,
1995) in coloncancer tissues. In a case report(Yamamoto etal,1997),
in a patient with colon adenocarcinoma who showed no evidence of
prostate cancer, there were high PSA levels preoperatively that
returned to normal level after total removal of the cancer.
In this study, to our knowledge for the ﬁrst time in the litera-
ture, preoperative serum total and free PSA concentrations were
measured in women with colorectal carcinoma, and the relation-
ship with clinicopathological features and the diagnostic value of
these markers were investigated.
MATERIALS AND METHODS
Patients
Between June 1998 and December 2000, serum total and free PSA
levels were measured preoperatively in 75 women with colorectal
carcinoma and with no other pathology (mean age 60 years, range
27–82 years), who were operated at SSK Okmeydanı Training
Hospital, I
.
stanbul, and in 30 ‘healthy’ women (mean age 40.4
years, range 17–69 years). All women included in the study had
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the tumour could be resected while six tumours were unresectable
due to adjacent organ and structure invasion. The location, size
and histologic features of the tumour were reported by the referred
pathologist. The size and histologic features of the unresected
tumours were not included in the evaluation. Venous invasion
was not examined in one of the resected tumours. Histologic type
was divided in two subgroups as well-differentiated adenocarcino-
ma (15 cases) and the others. In the second group, there were 47
moderately and three poorly differentiated adenocarcinomas, three
mucinous carcinomas and one signet ring cell carcinoma. The
depth of invasion and staging of the disease were assessed accord-
ing to TNM system (Fleming et al, 1997). Two patients with
unresected tumours and with no distant metastasis were included
in advanced stage disease (stages III and IV).
PSA assays
Peripheral venous blood samples were drawn and centrifugated in
healthy women and 2 to 24 h before the operation in the colorectal
cancer patients. The collected sera were kept in 7208C until
analyzed. Total PSA measurements were performed with Coat-A-
Count
1 PSA IRMA (DPC, Los Angeles, CA, USA) kit and free
PSA measurements were performed with Coat-A-Count
1 Free
PSA IRMA (EURO/DPC Ltd, UK) kit, by utilizing solid-phase
sequential immunoradiometric assay which is based on monoclonal
and polyclonal anti-PSA antibodies. Lower detection limit for each
tumour marker was calculated as 0.01 ng ml
71 from the calibra-
tion curve by interpolation.
Statistics
The serum total and free PSA levels of 30 healthy women were
arranged in sequence from the lowest to highest and the marker
concentrations of the 28th woman were accepted as cut-off values
(speciﬁcity 93.3%). Marker levels exceeding these cut-off values
were considered as positive. Cases with a free PSA/total PSA ratio
over 50% were titled ‘free PSA predominant subject’.
Mann–Whitney U-Wilcoxon Rank Sum W test was used for
comparisons of total PSA or free PSA levels between colorectal
carcinoma patients and healthy women. The effect of age on total
PSA and free PSA levels was investigated using Spearman correla-
tion analysis. Fisher exact test was used for comparison of free PSA
predominancy between carcinoma patients and healthy women.
Chi-square test and Fisher exact test were used to assess the asso-
ciation between clinicopathological factors and total PSA positivity,
free PSA positivity or free PSA predominancy. P-values of less than
0.05 were considered to be statistically signiﬁcant.
RESULTS
PSA levels
As shown in Table 1, free PSA levels in women with colorectal
carcinoma were signiﬁcantly higher than healthy women
(P=0.006) whereas no signiﬁcant association existed in total PSA
levels of both groups. The ratio of free PSA predominant subjects
were 20% (15 out of 75) in colorectal carcinoma group and 3.3%
(one out of 30) in the healthy group (P=0.035). In colorectal carci-
noma patients and healthy women, total PSA and free PSA levels
decreased as age increased, though the correlations were not signif-
icant in Spearman analysis (data not shown).
Association between clinicopathological factors and PSA
positivities
The cut-off values for total PSA and free PSA were 0.34 ng ml
71
and 0.01 ng ml
71 respectively. Total PSA positivity was 20% (15
out of 75) and free PSA positivity was 34.6% (26 out of 75) in
women with colorectal carcinoma. As shown in Table 2, there
was no signiﬁcant association between total PSA positivity and
location and size of the tumour, depth of invasion or venous inva-
sion. The ratio of women younger than 50 years was slightly higher
in total PSA positives than negatives, but the difference was not
signiﬁcant (P=0.090). In total PSA positive patients, no well-differ-
entiated tumour existed, whereas 26.8% of total PSA negatives had
well-differentiated tumours (P=0.056). Compared to negatives, in
total PSA positive group, the ratio of the patients with lymph node
metastasis and advanced stage disease had a tendency to increase
(P=0.062 and P=0.070 respectively). There was no signiﬁcant asso-
ciation between clinicopathological variables and free PSA
positivity (data not shown).
Table 2 shows that no signiﬁcant association existed between
free PSA predominancy and age, location and size of the tumour,
venous invasion or lymph node involvement. In free PSA predomi-
nant patients, compared to patients with a1-antichymotripsin
bound PSA as the predominant molecular form, the ratio of well-
differentiated tumours were signiﬁcantly higher (P=0.014); the
ratios of T1–T 2 tumours (P=0.052) and early stage disease (stages
I and II) (P=0.090) were slightly higher.
DISCUSSION
In this initial report assessing serum total and free PSA levels in
women with colorectal carcinoma, total PSA levels were found to
be higher than healthy women but the difference was not signiﬁ-
cant. On the other hand free PSA levels were signiﬁcantly higher
in women with colorectal carcinoma.
PSA measurements in nonprostatic carcinomas have been
conducted mostly in women with breast cancer. It has been shown
that serum total PSA levels in women with breast cancer were
signiﬁcantly higher than healthy women, and in women with breast
cysts were signiﬁcantly higher than women with breast cancer and
serum free PSA levels in breast cancer patients were signiﬁcantly
higher than healthy women (Black et al, 2000). Another study
revealed serum total PSA concentrations to be signiﬁcantly lower
in women with breast cancer than women with benign breast
disease and no signiﬁcant difference was found between cancer
patients and normal women; free PSA levels showed no difference
in the groups (Borchert et al, 1997). In another study, no signiﬁ-
cant difference in serum total PSA levels was found between
breast cancer patients and women with benign breast disease or
healthy women (Romppanen et al, 1999).
Total PSA is the sum of different molecular forms of PSA
existing in serum, that is, free (non-complexed) PSA and PSA
complexed to a1-1-antichymotripsin. Recently, it has been
demonstrated that free PSA/total PSA ratio in prostate cancer
patients is lower than patients with benign prostatic hyperplasia
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Table 1 Total PSA and free PSA levels (ng ml
71) in female colorectal
carcinoma patients and healthy women
Range
n min
a max
b Mean s.d.
c Median P
Total PSA
Colorectal carcinoma 75 0.01 2.5 0.289 0.500 0.10
0.375
Healthy women 30 0.01 1.7 0.175 0.313 0.08
Free PSA
Colorectal carcinoma 75 0.01 0.40 0.032 0.062 0.01
0.006
Healthy women 30 0.01 0.08 0.013 0.013 0.01
Statistical test used is Mann–Whitney U-Wilcoxon Rank Sum W test.
amin=minimum;
bmax=maximum;
cs.d.=standard deviation.
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ity of prostate cancer diagnosis (Catalona et al, 1995; To ¨rnblom
et al, 1999; Veltri and Miller, 1999). Cut-off values proposed for
per cent free PSA have ranged from 17 to 25% (Kamoi and
Babaian, 1999).
Studies conducted in women with breast cancer revealed
contrary results. It was demonstrated that 44% of women with
breast cancer and 58% of women with benign breast disease had
serum free PSA as the major molecular form, whereas normal
women had PSA bound to a1-antichymotripsin as the major mole-
cular form, and it was suggested that the ratio of free PSA/bound
PSA might have value for diagnosis of breast diseases including
breast cancer (Borchert et al, 1997). In another study (Black et
al, 2000), it was demonstrated that the percentage (20%) of breast
cancer patients with free PSA as the predominant molecular form
(450% of total PSA) in serum was signiﬁcantly higher than that of
healthy women (3%) or women with benign breast disease (4%),
and it was stated that although free PSA as the predominant mole-
cular form has high speciﬁcity (96%), its clinical utility is limited
due to low sensitivity (20%).
We concluded similar results as with the study mentioned above
(Black et al, 2000), in our study. The percentage of free PSA predo-
minant subjects (free PSA/total PSA 450%) in women with
colorectal carcinoma was 20%, which was signiﬁcantly higher than
healthy women (3.3%). Although the sensitivity of free PSA predomi-
nancy was low (20%) in distinguishing women with colorectal
carcinoma than healthy women, the speciﬁcity was higher (96.7%)
which justiﬁes further investigations to clarify its clinical signiﬁcance.
In our study, although serum total and free PSA levels were
decreased as age increased both in women with colorectal carcinoma
and healthy women, the correlations were not signiﬁcant; the percen-
tage of women older than 50 years was slightly lower in total PSA
positive patients than negatives. In one study serum total PSA levels
were found to decrease signiﬁcantly with ageing in both healthy
women and women with breast cancer (Romppanen et al, 1999).
However, in another study no signiﬁcant correlation was found
between serum total PSA levels and age in normal women while a
negative correlation was demonstrated in women with breast cancer
(Borchert et al, 1997). As in the explanation of the decrease of PSA
expression with ageing in breast cancer tissue (Yu et al, 1994a), the
decrease in PSA production with ageing might be due to the decrease
of ovarian hormones which mediate PSA production by binding to
the steroid receptors found in colorectal cancer tissue.
The cut-off values providing the speciﬁcity rate of 93.3% in our
series, were 0.34 ng ml
71 for total PSA and 0.01 ng ml
71 for free
PSA. The cut-off value in breast cancer diagnosis for total PSA is
30 ng ml
71 (Borchert et al, 1997; Romppanen et al, 1999) which
is 10 times lower than the value we found. This discrimination
may be due to the difference in the sensitivities of PSA assays. With
our cut-off values, in our series, total PSA positivity was 20% and
free PSA positivity was 34.6% in women with colorectal carcinoma.
With a cut-off value of 30 ng ml
71 total PSA positivity rates were
reported to be 6.5% (Borchert et al, 1997) and 5.6% (Romppanen
et al, 1999) in women with breast cancer.
We did not ﬁnd any signiﬁcant association with serum total
PSA levels and the location, tumour size, depth of wall invasion
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Table 2 The association between clinicopathological factors and total PSA positivity or free PSA predominancy
Total PSA (+) Total PSA (7) Free PSA 450% Free PSA 550%
Factor n % n % Pn % n % P
Age (years)
550 6 40.0 11 18.3 3 20.0 14 23.3
0.090 NS
a
550 9 60.0 49 81.7 12 80.0 46 76.7
Location
Colon 6 40.0 27 45.0 6 40.0 27 45.0
NS
a NS
a
Rectum 9 60.0 33 55.0 9 60.0 33 55.0
Tumour size (cm)
45 5 38.5 30 53.6 10 66.7 25 46.3
NS
a NS
a
45 8 61.5 26 46.4 5 33.0 29 53.7
Histologic type
Well differentiated 0 0.0 15 26.8 7 46.7 8 14.8
0.056 0.014
Others 13 100.0 41 73.2 8 53.3 46 85.2
Depth of invasion
T1–T 2 2 15.4 16 28.6 7 46.7 11 20.4
NS
a 0.052
T3–T 4 11 84.6 40 71.4 8 53.3 43 79.6
Venous invasion
Negative 11 84.6 42 76.4 12 80.0 41 77.4
NS
a NS
a
Positive 2 15.4 13 23.6 3 20.0 12 22.6
Lymph node metastasis
Negative 5 38.5 38 67.9 12 80.0 31 57.4
0.062 NS
a
Positive 8 61.5 18 32.1 3 20.0 23 42.6
Stage
I–II 5 33.3 38 63.3 12 80.0 31 51.7
0.070 0.090
III–IV 10 66.7 22 36.7 3 20.0 29 48.3
Statistical methods used are chi-square test and Fisher exact test.
aNS=not signiﬁcant.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 203–206or venous invasion. There was no well-differentiated tumour in
total PSA positive patients while 26.8% of the negative patients
had well-differentiated tumours, the difference was nearly signiﬁ-
cant. In total PSA positive patients compared to negatives, there
was a tendency to be in advanced stage disease and lymph node
metastasis. No signiﬁcant association could be found between
free PSA positivity and the clinicopathological features. Well-
differentiated tumours were signiﬁcantly higher in patients with
predominant free PSA; there was a tendency to be T1–T 2 and
early stage tumours in this group. There was no signiﬁcant asso-
ciation with free PSA predominancy and other clinicopathological
factors.
No signiﬁcant relationship was found in breast cancer patients
between serum total PSA levels and histologic grade or disease
stage (Borchert et al, 1997; Romppanen et al, 1999). In another
study no association was found between histologic grade and
serum total PSA or free PSA predominancy (Black et al, 2000).
In accordance with our results, it has been shown that in prostate
cancer patients, the aggressiveness of the histologic grade increased
signiﬁcantly as the percentage of free PSA/total PSA decreased (Li
et al, 1999).
In summary, with a speciﬁcity rate of 93.3%, the sensitivity rate
for serum total PSA was 20% and for serum free PSA, it was
34.6% in women with colorectal carcinoma. Free PSA predomi-
nancy (free PSA/total PSA 450%) showed a sensitivity rate of
20% and a speciﬁcity rate of 96.7% in distinguishing women with
colorectal carcinoma than healthy women. Although total PSA
positivity had a tendency to be present in aggressive histologic
types and in advanced stage tumours, free PSA predominancy
had a tendency to be present in well-differentiated and early stage
tumours.
In conclusion, this data reveals that preoperative serum total and
free PSA measurements may offer clinical signiﬁcance in women
with colorectal carcinoma and there is need for new studies includ-
ing wider patient and control groups, utilizing ultrasensitive PSA
assays whose lowest detection limit is lower.
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